ADIPONECTIN VERSUS THIAZOLIDINEDIONES AND ANGIOTENSIN RECEPTOR BLOCKERS

  • S. Afzal School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia
  • M. A. Sattar School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia
  • H. A. Rathore School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia
  • Abdullah Ijaz Hussain School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia Department of Chemistry, Government College University, Faisalabad, Pakistan
  • Ashfaq Ahmad School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia
  • Aqeel Javeed Department of Pharmacology and Toxicology, UVAS, Lahore, Pakistan
  • Fiaz-ud-din Ahmad School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia
  • Edward J. Johns Universitt College Cork, Ireland, Ireland
  • Safia Akhtar School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia

Abstract

Adipose tissue has gained great attention during the last decade. It represents not only a depot for energy stores, but also releases adipocytokines regulating energy disposal and can therefore be considered from therapeutic point of view. Hypoadiponectemia is an independent threat for development of metabolic syndrome. When subjects treated with antidiabetic (Thiazolidinediones) and antihypertensive (angiotensin receptor blocker) agents , the plasma concentration of adiponectin, the only component of adipocytokines, directly proportional to plasma values of these drugs. The prevalance of hypertension and T2DM is mounting with unprecedented degree in both developing and advanced countries, therefore, there is a dire need to find safer and economical therapeutic regimes for the treatment of these ailments, and intensive research is also underway for this purpose. PPARĪ³ serves as a common link in the actions of ADN, TZDs and ARBs when exerting their effects, and it is responsible for stimulation of adiponectin receptors, thus ultimately enhancing the levels of adiponectin in plasma. This review aims to elucidate the role, link and use of ARBs, ADN and TZDs as a safer and convenient approach for the treatment of these co-morbidities as a unanimous or single remedy from comparative point of view.

Downloads

Download data is not yet available.
Published
2013-08-31
How to Cite
Afzal, S., Sattar, M. A., Rathore, H. A., Hussain, A. I., Ahmad, A., Javeed, A., Ahmad, F.- ud- din, J. Johns, E., & Akhtar, S. (2013). ADIPONECTIN VERSUS THIAZOLIDINEDIONES AND ANGIOTENSIN RECEPTOR BLOCKERS. European Scientific Journal, ESJ, 9(24). https://doi.org/10.19044/esj.2013.v9n24p%p